Adjuvanted rabies vaccine with improved viscosity profile

A single-dose adjuvanted Rabies virus vaccine composition consisting essentially of an attenuated recombinant Orthopox or Avipox viral vector and a trimethylated chitosan (TMC) adjuvant, wherein the vector expresses in an animal host a full-length G protein from the ERA Rabies virus strain;

• and
• wherein the TMC is present in an amount at about 2.5% w/v;
• wherein the presence of the adjuvant is associated with both increased viscosity and increased protective efficacy against subsequent experimental or natural challenge with virulent Rabies virus, as compared to an otherwise equivalent composition, wherein the adjuvant has been omitted;
• and
• wherein the single-dose elicits in at least 90% of the animals protective levels of Rabies virus specific neutralizing antibodies within 90 days of administration of the single-dose composition.